Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226223 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenetics of Naltrexone for Stimulant Abuse
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT03226223 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 18 participants.
The verdict
NCT03226223, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This investigation will be the first study assessing genetic modulation of naltrexone's NTX effects upon the abuse liability of a stimulant drug (methamphetamine). The study team will assess the ability of oral NTX to block the reinforcing and positive subjective effects of intranasal (IN) methamphetamine (30mg/70kg). This investigation could identify an important Gene x Pharmacological interaction, contributing to the personalization of stimulant abuse pharmacotherapy.
Interventions
- DRUG Intranasal Methamphetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2020-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03226223
The ClinicalTrials.gov registry entry for NCT03226223 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intranasal Methamphetamine is the first listed.
NCT03226223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03226223 about?
NCT03226223 is a clinical study titled "Pharmacogenetics of Naltrexone for Stimulant Abuse". This investigation will be the first study assessing genetic modulation of naltrexone's NTX effects upon the abuse liability of a stimulant drug (methamphetamine). The study team will assess the ability of oral NTX to block the reinforcing and positive subjective effects of intranasal (IN) methamphe...
What is the current status of trial NCT03226223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-09-15. Estimated completion is 2020-07-30.
What interventions are being tested in trial NCT03226223?
The interventions under investigation include: Intranasal Methamphetamine (DRUG).
Who is sponsoring clinical trial NCT03226223?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.